Table 2_Hepatic arterial interventional therapies alone or in combination with molecular targeted therapies and PD-(L)1 inhibitors in locally aggressive, early recurrent hepatocellular carcinoma: a retrospective study.docx
Background<p>Current treatment strategies for locally aggressive (beyond Milan criteria), early recurrent hepatocellular carcinoma (erHCC) lack consensus. This study aims to compare the efficacy of hepatic arterial interventional therapies (HAIT) combined with molecular targeted therapies and...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , , , , |
| Published: |
2025
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1852016687336914944 |
|---|---|
| author | Weixin Luo (11404944) |
| author2 | Lixuan Liu (6444710) Wenping Lin (11900064) Jie Mei (153449) Yansong Lin (2605975) Zhoutian Yang (15234629) Fangyi Liu (3947564) Wei Wei (21173) Rongping Guo (11900073) Jingping Yun (111732) |
| author2_role | author author author author author author author author author |
| author_facet | Weixin Luo (11404944) Lixuan Liu (6444710) Wenping Lin (11900064) Jie Mei (153449) Yansong Lin (2605975) Zhoutian Yang (15234629) Fangyi Liu (3947564) Wei Wei (21173) Rongping Guo (11900073) Jingping Yun (111732) |
| author_role | author |
| dc.creator.none.fl_str_mv | Weixin Luo (11404944) Lixuan Liu (6444710) Wenping Lin (11900064) Jie Mei (153449) Yansong Lin (2605975) Zhoutian Yang (15234629) Fangyi Liu (3947564) Wei Wei (21173) Rongping Guo (11900073) Jingping Yun (111732) |
| dc.date.none.fl_str_mv | 2025-09-12T05:34:41Z |
| dc.identifier.none.fl_str_mv | 10.3389/fimmu.2025.1643082.s002 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/dataset/Table_2_Hepatic_arterial_interventional_therapies_alone_or_in_combination_with_molecular_targeted_therapies_and_PD-_L_1_inhibitors_in_locally_aggressive_early_recurrent_hepatocellular_carcinoma_a_retrospective_study_docx/30110791 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Genetic Immunology hepatocellular carcinoma early recurrence Milan criteria immune checkpoint inhibitor hepatic arterial interventional therapy molecular targeted therapy |
| dc.title.none.fl_str_mv | Table 2_Hepatic arterial interventional therapies alone or in combination with molecular targeted therapies and PD-(L)1 inhibitors in locally aggressive, early recurrent hepatocellular carcinoma: a retrospective study.docx |
| dc.type.none.fl_str_mv | Dataset info:eu-repo/semantics/publishedVersion dataset |
| description | Background<p>Current treatment strategies for locally aggressive (beyond Milan criteria), early recurrent hepatocellular carcinoma (erHCC) lack consensus. This study aims to compare the efficacy of hepatic arterial interventional therapies (HAIT) combined with molecular targeted therapies and PD-(L)1 inhibitors (HAIT-M-P) versus HAIT alone for locally aggressive erHCC.</p>Methods<p>This study retrospectively reviewed the data of locally aggressive erHCC patients treated with HAIT alone or HAIT-M-P at Sun Yat-sen University Cancer Center from 2020 to 2024. The progression-free survival (PFS), overall survival (OS), tumor responses, and treatment-related adverse events (TRAEs) were compared. Propensity score matching (PSM) and multivariate Cox regression model were used to minimize confounding bias.</p>Results<p>A total of 101 patients with locally aggressive erHCC were enrolled. Compared with the HAIT group (n=51), the HAIT-M-P group (n=50) demonstrated significantly longer median PFS (10.1 months vs. 3.7 months, HR = 0.36, P < 0.001) and comparable median OS (not reached vs. 38.2 months, HR = 0.45, P = 0.065). After PSM, 24 pairs of patients were included. The HAIT-M-P group maintained a significant median PFS advantage (12.8 months vs. 3.7 months, HR = 0.28, P < 0.001) and comparable median OS (not reached vs. 38.2 months, HR = 0.56, P = 0.330). In the multivariate Cox regression analysis, the HAIT-M-P group demonstrated a significant improvement in OS (HR = 0.30, P = 0.033). The objective response rate and disease control rate were significantly higher in the HAIT-M-P group than in the HAIT group, respectively, according to the RECIST v1.1 (30.0% vs. 7.8%, P = 0.009; 82.0% vs. 54.9%, P = 0.007) and mRECIST criteria (56.0% vs. 19.6%, P < 0.001; 90.0% vs. 58.8%, P = 0.001). The grade 3 – 4 TRAEs between the two groups were comparable (19.6% vs. 34.0%, P = 0.159).</p>Conclusion<p>Compared with HAIT alone, HAIT-M-P was associated with improved PFS and tumor response rates, and showed a possible trend toward improved OS in patients with locally aggressive erHCC, which warrants further validation.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_2dc75ca477a45a67d01b85e75ccfe77a |
| identifier_str_mv | 10.3389/fimmu.2025.1643082.s002 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30110791 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Table 2_Hepatic arterial interventional therapies alone or in combination with molecular targeted therapies and PD-(L)1 inhibitors in locally aggressive, early recurrent hepatocellular carcinoma: a retrospective study.docxWeixin Luo (11404944)Lixuan Liu (6444710)Wenping Lin (11900064)Jie Mei (153449)Yansong Lin (2605975)Zhoutian Yang (15234629)Fangyi Liu (3947564)Wei Wei (21173)Rongping Guo (11900073)Jingping Yun (111732)Genetic Immunologyhepatocellular carcinomaearly recurrenceMilan criteriaimmune checkpoint inhibitorhepatic arterial interventional therapymolecular targeted therapyBackground<p>Current treatment strategies for locally aggressive (beyond Milan criteria), early recurrent hepatocellular carcinoma (erHCC) lack consensus. This study aims to compare the efficacy of hepatic arterial interventional therapies (HAIT) combined with molecular targeted therapies and PD-(L)1 inhibitors (HAIT-M-P) versus HAIT alone for locally aggressive erHCC.</p>Methods<p>This study retrospectively reviewed the data of locally aggressive erHCC patients treated with HAIT alone or HAIT-M-P at Sun Yat-sen University Cancer Center from 2020 to 2024. The progression-free survival (PFS), overall survival (OS), tumor responses, and treatment-related adverse events (TRAEs) were compared. Propensity score matching (PSM) and multivariate Cox regression model were used to minimize confounding bias.</p>Results<p>A total of 101 patients with locally aggressive erHCC were enrolled. Compared with the HAIT group (n=51), the HAIT-M-P group (n=50) demonstrated significantly longer median PFS (10.1 months vs. 3.7 months, HR = 0.36, P < 0.001) and comparable median OS (not reached vs. 38.2 months, HR = 0.45, P = 0.065). After PSM, 24 pairs of patients were included. The HAIT-M-P group maintained a significant median PFS advantage (12.8 months vs. 3.7 months, HR = 0.28, P < 0.001) and comparable median OS (not reached vs. 38.2 months, HR = 0.56, P = 0.330). In the multivariate Cox regression analysis, the HAIT-M-P group demonstrated a significant improvement in OS (HR = 0.30, P = 0.033). The objective response rate and disease control rate were significantly higher in the HAIT-M-P group than in the HAIT group, respectively, according to the RECIST v1.1 (30.0% vs. 7.8%, P = 0.009; 82.0% vs. 54.9%, P = 0.007) and mRECIST criteria (56.0% vs. 19.6%, P < 0.001; 90.0% vs. 58.8%, P = 0.001). The grade 3 – 4 TRAEs between the two groups were comparable (19.6% vs. 34.0%, P = 0.159).</p>Conclusion<p>Compared with HAIT alone, HAIT-M-P was associated with improved PFS and tumor response rates, and showed a possible trend toward improved OS in patients with locally aggressive erHCC, which warrants further validation.</p>2025-09-12T05:34:41ZDatasetinfo:eu-repo/semantics/publishedVersiondataset10.3389/fimmu.2025.1643082.s002https://figshare.com/articles/dataset/Table_2_Hepatic_arterial_interventional_therapies_alone_or_in_combination_with_molecular_targeted_therapies_and_PD-_L_1_inhibitors_in_locally_aggressive_early_recurrent_hepatocellular_carcinoma_a_retrospective_study_docx/30110791CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/301107912025-09-12T05:34:41Z |
| spellingShingle | Table 2_Hepatic arterial interventional therapies alone or in combination with molecular targeted therapies and PD-(L)1 inhibitors in locally aggressive, early recurrent hepatocellular carcinoma: a retrospective study.docx Weixin Luo (11404944) Genetic Immunology hepatocellular carcinoma early recurrence Milan criteria immune checkpoint inhibitor hepatic arterial interventional therapy molecular targeted therapy |
| status_str | publishedVersion |
| title | Table 2_Hepatic arterial interventional therapies alone or in combination with molecular targeted therapies and PD-(L)1 inhibitors in locally aggressive, early recurrent hepatocellular carcinoma: a retrospective study.docx |
| title_full | Table 2_Hepatic arterial interventional therapies alone or in combination with molecular targeted therapies and PD-(L)1 inhibitors in locally aggressive, early recurrent hepatocellular carcinoma: a retrospective study.docx |
| title_fullStr | Table 2_Hepatic arterial interventional therapies alone or in combination with molecular targeted therapies and PD-(L)1 inhibitors in locally aggressive, early recurrent hepatocellular carcinoma: a retrospective study.docx |
| title_full_unstemmed | Table 2_Hepatic arterial interventional therapies alone or in combination with molecular targeted therapies and PD-(L)1 inhibitors in locally aggressive, early recurrent hepatocellular carcinoma: a retrospective study.docx |
| title_short | Table 2_Hepatic arterial interventional therapies alone or in combination with molecular targeted therapies and PD-(L)1 inhibitors in locally aggressive, early recurrent hepatocellular carcinoma: a retrospective study.docx |
| title_sort | Table 2_Hepatic arterial interventional therapies alone or in combination with molecular targeted therapies and PD-(L)1 inhibitors in locally aggressive, early recurrent hepatocellular carcinoma: a retrospective study.docx |
| topic | Genetic Immunology hepatocellular carcinoma early recurrence Milan criteria immune checkpoint inhibitor hepatic arterial interventional therapy molecular targeted therapy |